Lineage Cell Therapeutics Inc. (TASE: LCTX) (NYSE: LCTX) Starts Presentation at NobleCon16
Lineage Cell Therapeutics (TASE: LCTX) (NYSE: LCTX) is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Using its proprietary cell-based therapy platform and associated development and manufacturing capabilities, Lineage develops and manufactures specialized, terminally differentiated human cells developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical assets include: OpRegen®, in phase I/IIa development for the treatment of dry age-related macular degeneration; OPC1, in phase I/IIa development for the…







